CSL Behring is 2016
‘Victorian Manufacturer of the Year’ CSL Behring operates two plasma product manufacturing facilities and a Biotechnology Manufacturing Facility at its 24 ha site in Broadmeadows Victoria

10-June-2016 — Last night CSL Behring’s Australian facility was awarded ‘2016 Victorian Manufacturer of the Year’ at the Victorian Manufacturing Hall of Fame Awards. More.

Seqirus donates vaccines to Fiji to alleviate increase in influenza The Seqirus site in Melbourne

06-June-2016 — Through a request facilitated by the World Health Organisation’s Emerging Diseases Surveillance and Response Unit in Fiji, CSL has been able to provide an immediate donation of influenza vaccine manufactured at its facility in Melbourne, Australia. More.

Other recent news:

01-June-2016 — Call for applications for CSL Centenary Fellowships. Two five-year fellowships awarded each calendar year, for ten years. More.
26-May-2016 — The US Food and Drug Administration (FDA) has approved CSL Behring's AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain]. More.
24-May-2016 — The US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine),  More.
12-May-2016 — The European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B. More.

© 2016 CSL Limited